Wedbush raised the firm’s price target on Opus Genetics (IRD) to $10 from $8 and keeps an Outperform rating on the shares. The firm notes the Q4 update recapped the recent progress across all pipeline programs. Wedbush sees Opus as making good progress on all fronts, and the firm has increased its estimated Probability of Success for the OPGx-BEST1 program from 10% to 35% based on the positive initial data and a strengthened balance sheet.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Buy Rating on Opus Genetics Driven by Advancing Gene Therapy Pipeline, Near‑Term Clinical Catalysts, and Solid Cash Runway
- Opus Genetics: Advancing Late-Stage Gene Therapy Pipeline and 2026 Data Catalysts Support Buy Rating and $10 Target
- Opus Genetics reports FY25 EPS (80c) vs ($2.15) last year
- Opus Genetics price target raised to $12 from $7 at BTIG
- Opus Genetics announces initial data from Phase 1/2 study of OPGx-BEST1